{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:26:32Z","timestamp":1785767192083,"version":"3.56.0"},"reference-count":157,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2025.2077","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:14:32Z","timestamp":1761729272000},"page":"1-15","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive overview of alternative medicine in the treatment of ankylosing spondylitis: Symptoms, pathogenesis, diagnosis and treatments (Review)"],"prefix":"10.3892","volume":"24","author":[{"given":"So","family":"Park","sequence":"first","affiliation":[{"name":"Department of Korean Medicine, College of Korean Medicine, Woosuk University, Jeonju, Jeollabuk-do 54986, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Korean Medicine, College of Korean Medicine, Woosuk University, Jeonju, Jeollabuk-do 54986, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunju","family":"So","sequence":"additional","affiliation":[{"name":"Department of Korean Medicine, College of Korean Medicine, Woosuk University, Jeonju, Jeollabuk-do 54986, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Korean Medicine, College of Korean Medicine, Woosuk University, Jeonju, Jeollabuk-do 54986, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Korean Medicine, College of Korean Medicine, Woosuk University, Jeonju, Jeollabuk-do 54986, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Korean Medicine, College of Korean Medicine, Woosuk University, Jeonju, Jeollabuk-do 54986, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"22","key":"key20251209132223_b1-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: Etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res"},{"key":"key20251209132223_b2-BR-24-1-02077","author":"Van Royen"},{"key":"key20251209132223_b3-BR-24-1-02077","first-page":"742","article-title":"Ankylosing spondylitis and uveitis: Overview","volume":"52","author":"Gouveia","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"key20251209132223_b4-BR-24-1-02077","first-page":"613","article-title":"Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German collaborative arthritis centers","volume":"27","author":"Zink","year":"2000","journal-title":"J Rheumatol"},{"key":"key20251209132223_b5-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landewe","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b6-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4078\/jrd.2023.0041","article-title":"Updates on ankylosing spondylitis: Pathogenesis and therapeutic agents","volume":"30","author":"Kim","year":"2023","journal-title":"J Rheum Dis"},{"key":"key20251209132223_b7-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40265-018-0971-x","article-title":"Beyond the TNF-\u03b1 inhibitors: New and emerging targeted therapies for patients with axial spondyloarthritis and their relation to pathophysiology","volume":"78","author":"Pedersen","year":"2018","journal-title":"Drugs"},{"issue":"1232","key":"key20251209132223_b8-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01232","article-title":"Editorial: Ankylosing spondylitis and related immune-mediated disorders","volume":"10","author":"Fiorillo","year":"2019","journal-title":"Front Immunol"},{"issue":"221","key":"key20251209132223_b9-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1724-7","article-title":"Influence of HLA-B27 on the ankylosing spondylitis phenotype: Results from the REGISPONSER database","volume":"20","author":"Ar\u00e9valo","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"key20251209132223_b10-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3892\/mmr.2017.6248","article-title":"Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review)","volume":"15","author":"Chen","year":"2017","journal-title":"Mol Med Rep"},{"key":"key20251209132223_b11-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10067-014-2662-7","article-title":"An update on the contribution of the MHC to AS susceptibility","volume":"33","author":"Reveille","year":"2014","journal-title":"Clin Rheumatol"},{"key":"key20251209132223_b12-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","article-title":"Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b13-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.berh.2006.03.003","article-title":"Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy","volume":"20","author":"Akkoc","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20251209132223_b14-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/OARRR.S295033","article-title":"Therapeutic targets for ankylosing spondylitis-recent insights and future prospects","volume":"14","author":"Perrotta","year":"2022","journal-title":"Open Access Rheumatol"},{"issue":"e52559","key":"key20251209132223_b15-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52559","article-title":"Diagnosis and treatment of ankylosing spondylitis","volume":"16","author":"Agrawal","year":"2024","journal-title":"Cureus"},{"key":"key20251209132223_b16-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5371\/hp.2014.26.3.129","article-title":"Medical treatment of ankylosing spondylitis","volume":"26","author":"Moon","year":"2014","journal-title":"Hip Pelvis"},{"key":"key20251209132223_b17-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"key20251209132223_b18-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.semarthrit.2008.08.001","article-title":"Nonsteroidal anti-inflammatory drugs: Adverse effects and their prevention","volume":"39","author":"Vonkeman","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"e000762","key":"key20251209132223_b19-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000762","article-title":"Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: A population-based nationwide study","volume":"4","author":"Lindstr\u00f6m","year":"2018","journal-title":"RMD Open"},{"key":"key20251209132223_b20-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"key20251209132223_b21-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41584-019-0309-4","article-title":"The role of imaging in the diagnosis and management of axial spondyloarthritis","volume":"15","author":"Maksymowych","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"key20251209132223_b22-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"key20251209132223_b23-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"issue":"603726","key":"key20251209132223_b24-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.603726","article-title":"Perspectives on the genetic associations of ankylosing spondylitis","volume":"12","author":"Wordsworth","year":"2021","journal-title":"Front Immunol"},{"key":"key20251209132223_b25-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"vi4","DOI":"10.1093\/rheumatology\/key001","article-title":"Progress in our understanding of the pathogenesis of ankylosing spondylitis","volume":"57 (Suppl 6)","author":"Simone","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"key20251209132223_b26-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.iy.13.040195.003103","article-title":"The three-dimensional structure of peptide-MHC complexes","volume":"13","author":"Madden","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"key20251209132223_b27-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","article-title":"Hla-B27","volume":"33","author":"Bowness","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"key20251209132223_b28-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00296-017-3741-2","article-title":"Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: A meta-analysis","volume":"37","author":"Lin","year":"2017","journal-title":"Rheumatol Int"},{"key":"key20251209132223_b29-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.autrev.2011.01.011","article-title":"What is the role of HLA-B27 in spondyloarthropathies?","volume":"10","author":"Chatzikyriakidou","year":"2011","journal-title":"Autoimmun Rev"},{"key":"key20251209132223_b30-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/art.27188","article-title":"The HLA-B27 peptidome: Building on the cornerstone","volume":"62","author":"L\u00f3pez de Castro","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20251209132223_b31-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2013.07.013","article-title":"HLA-B27 misfolding and ankylosing spondylitis","volume":"57","author":"Colbert","year":"2014","journal-title":"Mol Immunol"},{"key":"key20251209132223_b32-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/pri.3.1.8072","article-title":"HLA-B27 misfolding and spondyloarthropathies","volume":"3","author":"Colbert","year":"2009","journal-title":"Prion"},{"key":"key20251209132223_b33-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/ars.2010.3693","article-title":"The MHC class I heavy chain structurally conserved cysteines 101 and 164 participate in HLA-B27 dimer formation","volume":"16","author":"Lenart","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"key20251209132223_b34-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.4049\/jimmunol.175.4.2438","article-title":"HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response","volume":"175","author":"Turner","year":"2005","journal-title":"J Immunol"},{"issue":"422","key":"key20251209132223_b35-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00422","article-title":"Regulation of cytokine production by the unfolded protein response; implications for infection and autoimmunity","volume":"9","author":"Smith","year":"2018","journal-title":"Front Immunol"},{"issue":"601518","key":"key20251209132223_b36-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.601518","article-title":"Spondyloarthritis and the human leukocyte antigen (HLA)-B*27 connection","volume":"12","author":"Kavadichanda","year":"2021","journal-title":"Front Immunol"},{"key":"key20251209132223_b37-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1002\/art.34538","article-title":"Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis","volume":"64","author":"Payeli","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"486856","key":"key20251209132223_b38-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/486856","article-title":"Pathogenicity of misfolded and dimeric HLA-B27 molecules","volume":"2011","author":"Antoniou","year":"2011","journal-title":"Int J Rheumatol"},{"key":"key20251209132223_b39-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.micpath.2018.02.020","article-title":"The association of HLA-B27 and Klebsiella pneumoniae in ankylosing spondylitis: A systematic review","volume":"117","author":"Zhang","year":"2018","journal-title":"Microb Pathog"},{"key":"key20251209132223_b40-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/01.bor.0000231899.81677.04","article-title":"The genetic basis of ankylosing spondylitis","volume":"18","author":"Reveille","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"key20251209132223_b41-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/ard.2008.103804","article-title":"Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis","volume":"69","author":"Tsui","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b42-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mehy.2012.10.003","article-title":"Association of ankylosing spondylitis with HLA-B27 and ERAP1: Pathogenic role of antigenic peptide","volume":"80","author":"Chen","year":"2013","journal-title":"Med Hypotheses"},{"key":"key20251209132223_b43-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/ng.873","article-title":"Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility","volume":"43","author":"Evans","year":"2011","journal-title":"Nat Genet"},{"key":"key20251209132223_b44-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2567.2011.03453.x","article-title":"Expression of MHC class I dimers and ERAP1 in an ankylosing spondylitis patient cohort","volume":"133","author":"Campbell","year":"2011","journal-title":"Immunology"},{"key":"key20251209132223_b45-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness","year":"2011","journal-title":"J Immunol"},{"issue":"e163","key":"key20251209132223_b46-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.49","article-title":"Progress of genome-wide association studies of ankylosing spondylitis","volume":"6","author":"Li","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"key20251209132223_b47-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5045\/kjh.2011.46.4.216","article-title":"Human diversity of killer cell immunoglobulin-like receptors and disease","volume":"46","author":"Rajalingam","year":"2011","journal-title":"Korean J Hematol"},{"issue":"111","key":"key20251209132223_b48-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: A systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"key20251209132223_b49-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: From pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"key20251209132223_b50-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.biopha.2018.01.108","article-title":"Immune cells involved in the pathogenesis of ankylosing spondylitis","volume":"100","author":"Rezaiemanesh","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"key20251209132223_b51-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.immuni.2015.11.009","article-title":"Interleukin-23-induced transcription factor blimp-1 promotes pathogenicity of T helper 17 cells","volume":"44","author":"Jain","year":"2016","journal-title":"Immunity"},{"issue":"F1000 Faculty Rev-1512","key":"key20251209132223_b52-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14956.1","article-title":"Recent advances in ankylosing spondylitis: Understanding the disease and management","volume":"7","author":"Garcia-Montoya","year":"2018","journal-title":"F1000Res"},{"key":"key20251209132223_b53-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"key20251209132223_b54-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.imlet.2018.01.014","article-title":"The role of gut microbiota and IL-23\/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates","volume":"196","author":"Babaie","year":"2018","journal-title":"Immunol Lett"},{"key":"key20251209132223_b55-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nri2295","article-title":"TH17 cells in development: An updated view of their molecular identity and genetic programming","volume":"8","author":"Dong","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"key20251209132223_b56-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/14397595.2016.1206174","article-title":"New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications","volume":"27","author":"Mahmoudi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"key20251209132223_b57-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"623874","key":"key20251209132223_b58-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623874","article-title":"IL-23 inhibition in ankylosing spondylitis: Where did it go wrong?","volume":"11","author":"Baeten","year":"2021","journal-title":"Front Immunol"},{"key":"key20251209132223_b59-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/rheumatology\/kew384","article-title":"Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: A novel cytokine that could contribute to new bone formation in spondyloarthropathies","volume":"56","author":"El-Zayadi","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"350","key":"key20251209132223_b60-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0870-4","article-title":"High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation","volume":"17","author":"Lee","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"36","key":"key20251209132223_b61-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0394-3","article-title":"Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity","volume":"13","author":"Chen","year":"2015","journal-title":"J Transl Med"},{"issue":"e105684","key":"key20251209132223_b62-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105684","article-title":"HLA-B27 and human \u03b22-microglobulin affect the gut microbiota of transgenic rats","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"key20251209132223_b63-BR-24-1-02077","first-page":"361","article-title":"Role of gut microbiome in ankylosing spondylitis: an analysis of studies in literature","volume":"22","author":"Xu","year":"2016","journal-title":"Discov Med"},{"key":"key20251209132223_b64-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: A narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern Emerg Med"},{"key":"key20251209132223_b65-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature18847","article-title":"The microbiome and innate immunity","volume":"535","author":"Thaiss","year":"2016","journal-title":"Nature"},{"key":"key20251209132223_b66-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jbspin.2015.10.015","article-title":"Trafficking of antigens from gut to sacroiliac joints and spine in reactive arthritis and spondyloarthropathies: Mainly through lymphatics?","volume":"83","author":"Berthelot","year":"2016","journal-title":"Joint Bone Spine"},{"issue":"1154380","key":"key20251209132223_b67-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1154380","article-title":"Alterations in the gut virome in patients with ankylosing spondylitis","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"key20251209132223_b68-BR-24-1-02077","author":"Rome Ball"},{"key":"key20251209132223_b69-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/rheumatology\/24.3.242","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis: A comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis","volume":"24","author":"Goie The","year":"1985","journal-title":"Br J Rheumatol"},{"key":"key20251209132223_b70-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1759720X11436240","article-title":"Imaging in ankylosing spondylitis","volume":"4","author":"Ostergaard","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key20251209132223_b71-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b72-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1001\/archinte.160.19.2969","article-title":"Exercise and changes in health status in patients with ankylosing spondylitis","volume":"160","author":"Uhrin","year":"2000","journal-title":"Arch Intern Med"},{"issue":"CD011321","key":"key20251209132223_b73-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011321.pub2","article-title":"Exercise programmes for ankylosing spondylitis","volume":"10","author":"Regnaux","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"key20251209132223_b74-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/RHU.0000000000000499","article-title":"The effectiveness of structured group education on ankylosing spondylitis patients","volume":"23","author":"Kasapoglu Aksoy","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"key20251209132223_b75-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.23275","article-title":"Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs","volume":"58","author":"Song","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20251209132223_b76-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/187152312803476255","article-title":"Clinical pharmacology of non-steroidal anti-inflammatory drugs: A review","volume":"11","author":"Bacchi","year":"2012","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"key20251209132223_b77-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1189\/jlb.0310139","article-title":"Endogenous PGE2 promotes the induction of human Th17 responses by fungal \u00df-glucan","volume":"88","author":"Gagliardi","year":"2010","journal-title":"J Leukoc Biol"},{"key":"key20251209132223_b78-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/art.39298","article-title":"American college of rheumatology\/spondylitis association of america\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key20251209132223_b79-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20251209132223_b80-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b81-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"462","DOI":"10.18502\/jovr.v16i3.9440","article-title":"Ankylosing spondylitis","volume":"16","author":"Ebrahimiadib","year":"2021","journal-title":"J Ophthalmic Vis Res"},{"key":"key20251209132223_b82-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ncprheum0157","article-title":"Drug insight: Anti-tumor-necrosis-factor therapy for ankylosing spondylitis","volume":"2","author":"Henderson","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"675108","key":"key20251209132223_b83-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/675108","article-title":"Ankylosing spondylitis and rheumatoid arthritis: Serum levels of TNF-\u03b1 and Its soluble receptors during the course of therapy with etanercept and infliximab","volume":"2014","author":"Schulz","year":"2014","journal-title":"Biomed Res Int"},{"key":"key20251209132223_b84-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"key20251209132223_b85-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1517\/14656566.2011.604313","article-title":"Current therapeutics for spondyloarthritis","volume":"12","author":"Toussirot","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"key20251209132223_b86-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/TCRM.S53675","article-title":"Active axial spondyloarthritis: Potential role of certolizumab pegol","volume":"10","author":"Ranatunga","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"key20251209132223_b87-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"key20251209132223_b88-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20251209132223_b89-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1442","key":"key20251209132223_b90-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051442","article-title":"A new venue of TNF targeting","volume":"19","author":"Steeland","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20251209132223_b91-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"key":"key20251209132223_b92-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"key20251209132223_b93-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: New advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"key20251209132223_b94-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1172\/jci39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: Another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J Clin Invest"},{"key":"key20251209132223_b95-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"key20251209132223_b96-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"vi29","DOI":"10.1093\/rheumatology\/keab523","article-title":"New developments in ankylosing spondylitis-status in 2021","volume":"60","author":"Klavdianou","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"key20251209132223_b97-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14712598.2019.1554053","article-title":"Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis","volume":"19","author":"Wendling","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"key20251209132223_b98-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"e001005","key":"key20251209132223_b99-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-Year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"key20251209132223_b100-BR-24-1-02077","first-page":"260","article-title":"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-Year data from the MEASURE 2 study","volume":"37","author":"Deodhar","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"e152","key":"key20251209132223_b101-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections","volume":"6","author":"Kamm\u00fcller","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"key20251209132223_b102-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 Week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"key20251209132223_b103-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: Role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"key20251209132223_b104-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","article-title":"Bimekizumab: The first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis","volume":"33","author":"Reis","year":"2019","journal-title":"BioDrugs"},{"key":"key20251209132223_b105-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b106-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-Week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b107-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jaad.2015.08.057","article-title":"Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States","volume":"74","author":"Danesh","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key20251209132223_b108-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1517\/13543784.2012.690029","article-title":"JAK inhibition for the treatment of rheumatoid arthritis: A new era in oral DMARD therapy","volume":"21","author":"Vaddi","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"issue":"270","key":"key20251209132223_b109-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030270","article-title":"The use of janus kinase inhibitors in axial spondyloarthritis: Current insights","volume":"15","author":"Toussirot","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20251209132223_b110-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"7897263","key":"key20251209132223_b111-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7897263","article-title":"Selective immunomodulation of inflammatory pathways in keratinocytes by the janus kinase (JAK) inhibitor tofacitinib: implications for the employment of JAK-targeting drugs in psoriasis","volume":"2018","author":"Morelli","year":"2018","journal-title":"J Immunol Res"},{"key":"key20251209132223_b112-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20251209132223_b113-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.rdc.2017.04.006","article-title":"Genetics and the causes of ankylosing spondylitis","volume":"43","author":"Hanson","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"key20251209132223_b114-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/key128","article-title":"Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"key20251209132223_b115-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: One-year results of a double-blind, placebo-controlled study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"34","key":"key20251209132223_b116-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01001-1","article-title":"JAK inhibitors for axial spondyloarthritis: What does the future hold?","volume":"23","author":"Akkoc","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"key20251209132223_b117-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.18553\/jmcp.2020.26.10.1219","article-title":"Cost-effectiveness of treatment strategies with biologics in accordance with treatment guidelines for ankylosing spondylitis: A patient-level model","volume":"26","author":"Le","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"key20251209132223_b118-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14712598.2020.1704727","article-title":"Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: A narrative review","volume":"20","author":"Atzeni","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"key20251209132223_b119-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3899\/jrheum.200453","article-title":"Relation of NSAIDs, DMARDs, and TNF inhibitors for ankylosing spondylitis and psoriatic arthritis to risk of total hip and knee arthroplasty","volume":"48","author":"Stovall","year":"2021","journal-title":"J Rheumatol"},{"key":"key20251209132223_b120-BR-24-1-02077","first-page":"1","article-title":"Traditional Chinese medicine in treating Corona Virus Disease 2019: A systematic review and cost-effectiveness analysis","volume":"1","author":"Shao","year":"2023","journal-title":"Health Decis"},{"issue":"379291","key":"key20251209132223_b121-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/379291","article-title":"The mechanism of moxibustion: Ancient theory and modern research","volume":"2013","author":"Deng","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"key20251209132223_b122-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jams.2011.11.004","article-title":"Moxibustion at mingmen reduces inflammation and decreases IL-6 in a collagen-induced arthritis mouse model","volume":"5","author":"Kogure","year":"2012","journal-title":"J Acupunct Meridian Stud"},{"key":"key20251209132223_b123-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.13703\/j.0255-2930.2017.10.015","article-title":"Effects of moxibustion on Treg\/Th17 cell and its signal pathway in mice with rheumatoid arthritis","volume":"37","author":"Liu","year":"2017","journal-title":"Zhongguo Zhen Jiu"},{"issue":"4","key":"key20251209132223_b124-BR-24-1-02077","article-title":"Clinical research progress of acupuncture therapy in the treatment of ankylosing spondylitis","volume":"5","author":"Zhang","year":"2022","journal-title":"Med Theory Hypothesis"},{"issue":"113964","key":"key20251209132223_b125-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113964","article-title":"Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health","volume":"178","author":"Zhang","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"key20251209132223_b126-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jchromb.2015.12.050","article-title":"Current application of chemometrics in traditional Chinese herbal medicine research","volume":"1026","author":"Huang","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1135","key":"key20251209132223_b127-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22071135","article-title":"How can synergism of traditional medicines benefit from network pharmacology?","volume":"22","author":"Yuan","year":"2017","journal-title":"Molecules"},{"issue":"268","key":"key20251209132223_b128-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-14-268","article-title":"Anti-inflammatory activity of extracts of Bushen-Qiangdu-Zhilv decoction, a Chinese medicinal formula, in M1-polarized RAW264.7","volume":"14","author":"Huang","year":"2014","journal-title":"BMC Complement Altern Med"},{"issue":"337","key":"key20251209132223_b129-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1438-6","article-title":"Kunxian capsules in the treatment of patients with ankylosing spondylitis: A randomized placebo-controlled clinical trial","volume":"17","author":"Li","year":"2016","journal-title":"Trials"},{"issue":"114731","key":"key20251209132223_b130-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114731","article-title":"Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial","volume":"285","author":"Xie","year":"2022","journal-title":"J Ethnopharmacol"},{"issue":"13436","key":"key20251209132223_b131-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13723-3","article-title":"Dissecting the underlying pharmaceutical mechanism of Chinese traditional medicine Yun-Pi-Yi-Shen-Tong-Du-Tang acting on ankylosing spondylitis through systems biology approaches","volume":"7","author":"Xie","year":"2017","journal-title":"Sci Rep"},{"key":"key20251209132223_b132-BR-24-1-02077","first-page":"310","article-title":"Effect of xinfeng capsule on AS patients and their serum immunoglobulin subtypes and peripheral lymphocyte autophagy","volume":"36","author":"Ye","year":"2016","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"issue":"8796980","key":"key20251209132223_b133-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8796980","article-title":"Mechanism of xinfeng capsule in the treatment of hypercoagulable state of ankylosing spondylitis based on data mining and network pharmacology","volume":"2022","author":"Li","year":"2022","journal-title":"Biomed Res Int"},{"issue":"9709260","key":"key20251209132223_b134-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9709260","article-title":"The mechanism of \u2018treating different diseases with the same treatment\u2019 by qiangji jianpi decoction in ankylosing spondylitis combined with inflammatory bowel disease: A comprehensive analysis of multiple methods","volume":"2024","author":"Zhang","year":"2024","journal-title":"Gastroenterol Res Pract"},{"key":"key20251209132223_b135-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF00270250","article-title":"Enhanced interferon-gamma production by lymphocytes induced by a mitogen from mycoplasma arthritidis in patients with ankylosing spondylitis","volume":"9","author":"Seitz","year":"1989","journal-title":"Rheumatol Int"},{"key":"key20251209132223_b136-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3899\/jrheum.101257","article-title":"Interferon-\u03b3 contributes to HLA-B27-associated unfolded protein response in spondyloarthropathies","volume":"39","author":"Feng","year":"2012","journal-title":"J Rheumatol"},{"issue":"e21226","key":"key20251209132223_b137-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21226","article-title":"A literature review on Epimedium, a medicinal plant with promising slow aging properties","volume":"9","author":"Zhuang","year":"2023","journal-title":"Heliyon"},{"issue":"1628602","key":"key20251209132223_b138-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1628602","article-title":"Progress in the application of Epimedium and its major bioactive components in the treatment of orthopedic diseases","volume":"16","author":"Tong","year":"2025","journal-title":"Front Pharmacol"},{"key":"key20251209132223_b139-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11030-024-10877-x","article-title":"Exploring the molecular mechanism of Epimedium for the treatment of ankylosing spondylitis based on network pharmacology, molecular docking, and molecular dynamics simulations","volume":"29","author":"Wang","year":"2025","journal-title":"Mol Mol Divers"},{"issue":"e36146","key":"key20251209132223_b140-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36146","article-title":"Recent advances in Scutellariae radix: A comprehensive review on ethnobotanical uses, processing, phytochemistry, pharmacological effects, quality control and influence factors of biosynthesis","volume":"10","author":"Ma","year":"2024","journal-title":"Heliyon"},{"issue":"9887012","key":"key20251209132223_b141-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9887012","article-title":"Potential therapeutic mechanism of scutellaria baicalensis georgi against ankylosing spondylitis based on a comprehensive pharmacological model","volume":"2022","author":"Li","year":"2022","journal-title":"Biomed Res Int"},{"key":"key20251209132223_b142-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2174\/1381612822666161010105242","article-title":"Salvia miltiorrhiza: A potential red light to the development of cardiovascular diseases","volume":"23","author":"Wang","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"3816258","key":"key20251209132223_b143-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3816258","article-title":"Radix Salvia miltiorrhiza for ankylosing spondylitis: determining potential inflammatory molecular targets and mechanism using network pharmacology","volume":"2022","author":"Fang","year":"2022","journal-title":"Biomed Res Int"},{"issue":"1460","key":"key20251209132223_b144-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3390\/foods9101460","article-title":"Chrysanthemum indicum and Chrysanthemum morifolium: Chemical composition of their essential oils and their potential use as natural preservatives with antimicrobial and antioxidant activities","volume":"14","author":"Youssef","year":"2020","journal-title":"Foods"},{"issue":"1538311","key":"key20251209132223_b145-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1538311","article-title":"Exploring the antimicrobial, anti-inflammatory, antioxidant, and immunomodulatory properties of Chrysanthemum morifolium and Chrysanthemum indicum: A narrow review","volume":"16","author":"Liang","year":"2025","journal-title":"Front Pharmacol"},{"key":"key20251209132223_b146-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jep.2005.04.035","article-title":"Anti-inflammatory and immunomodulatory activities of the extracts from the inflorescence of Chrysanthemum indicum Linn\u00e9","volume":"101","author":"Cheng","year":"2005","journal-title":"J Ethnopharmacol"},{"issue":"8206281","key":"key20251209132223_b147-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8206281","article-title":"The protective effect of Chrysanthemum indicum extract against ankylosing spondylitis in mouse models","volume":"2017","author":"Dong","year":"2017","journal-title":"Biomed Res Int"},{"issue":"M1716","key":"key20251209132223_b148-BR-24-1-02077","article-title":"(2R,4aS,6aS,12bR,14aS,14bR)10-Hydroxy-N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxamide","volume":"2023","author":"Xie","year":"2023","journal-title":"Molbank"},{"key":"key20251209132223_b149-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1756-185X.13419","article-title":"Regulation of osteoblasts by alkaline phosphatase in ankylosing spondylitis","volume":"22","author":"Jo","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"key20251209132223_b150-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4078\/jrd.2023.0024","article-title":"Elevated BMPR2 expression amplifies osteoblast differentiation in ankylosing spondylitis","volume":"30","author":"Jo","year":"2023","journal-title":"J Rheum Dis"},{"key":"key20251209132223_b151-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2147\/DDDT.S97463","article-title":"Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro","volume":"10","author":"Zou","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"key20251209132223_b152-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1080\/13880209.2016.1216131","article-title":"Therapeutic potential of naringin: An overview","volume":"54","author":"Chen","year":"2016","journal-title":"Pharm Biol"},{"issue":"1759720X20966135","key":"key20251209132223_b153-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20966135","article-title":"Re-appraising the potential of naringin for natural, novel orthopedic biotherapies","volume":"12","author":"Yu","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key20251209132223_b154-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3892\/etm.2016.3410","article-title":"Protective effect of naringin against ankylosing spondylitis via ossification, inflammation and oxidative stress in mice","volume":"12","author":"Liu","year":"2016","journal-title":"Exp Ther Med"},{"issue":"4918239","key":"key20251209132223_b155-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4918239","article-title":"Punicalagin exerts protective effects against ankylosing spondylitis by regulating NF-\u03baB-TH17\/JAK2\/STAT3 signaling and oxidative stress","volume":"2020","author":"Feng","year":"2020","journal-title":"Biomed Res Int"},{"issue":"2228","key":"key20251209132223_b156-BR-24-1-02077","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02228","article-title":"Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte\/macrophage subsets","volume":"9","author":"Liu","year":"2018","journal-title":"Front Immunol"},{"key":"key20251209132223_b157-BR-24-1-02077","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.12659\/MSM.907589","article-title":"Protective effects of sinomenine against ankylosing spondylitis and the underlying molecular mechanisms","volume":"24","author":"Dong","year":"2018","journal-title":"Med Sci Monit"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:22:33Z","timestamp":1765279353000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2025.2077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,29]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2025.2077","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}